LMR Partners LLP Has $6.23 Million Stock Position in Agilent Technologies, Inc. (NYSE:A)

LMR Partners LLP cut its holdings in Agilent Technologies, Inc. (NYSE:A) by 43.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 41,935 shares of the medical research company’s stock after selling 32,115 shares during the quarter. LMR Partners LLP’s holdings in Agilent Technologies were worth $6,227,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of A. Quest Partners LLC grew its stake in shares of Agilent Technologies by 339.3% in the 3rd quarter. Quest Partners LLC now owns 6,862 shares of the medical research company’s stock valued at $1,019,000 after buying an additional 5,300 shares during the period. Thrivent Financial for Lutherans boosted its holdings in Agilent Technologies by 3.1% in the third quarter. Thrivent Financial for Lutherans now owns 292,789 shares of the medical research company’s stock worth $43,473,000 after acquiring an additional 8,874 shares in the last quarter. Mutual of America Capital Management LLC grew its stake in Agilent Technologies by 0.3% in the third quarter. Mutual of America Capital Management LLC now owns 50,306 shares of the medical research company’s stock valued at $7,469,000 after acquiring an additional 160 shares during the period. Natixis Advisors LLC increased its holdings in shares of Agilent Technologies by 15.7% during the third quarter. Natixis Advisors LLC now owns 113,991 shares of the medical research company’s stock valued at $16,926,000 after acquiring an additional 15,435 shares in the last quarter. Finally, Archer Investment Corp acquired a new position in shares of Agilent Technologies during the third quarter worth approximately $288,000.

Wall Street Analysts Forecast Growth

A has been the subject of several research reports. Wells Fargo & Company began coverage on shares of Agilent Technologies in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price target for the company. Evercore ISI boosted their target price on shares of Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. TD Cowen upped their target price on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Stifel Nicolaus reiterated a “buy” rating and set a $151.00 price target on shares of Agilent Technologies in a research note on Monday, August 26th. Finally, Citigroup increased their price objective on Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, Agilent Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $144.36.

Agilent Technologies Stock Down 0.1 %

A opened at $126.92 on Tuesday. The company has a fifty day moving average price of $138.50 and a 200-day moving average price of $137.92. Agilent Technologies, Inc. has a one year low of $112.39 and a one year high of $155.35. The firm has a market capitalization of $36.47 billion, a P/E ratio of 26.33, a price-to-earnings-growth ratio of 5.59 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.78 and a quick ratio of 1.37.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same period last year, the firm posted $1.43 earnings per share. Agilent Technologies’s quarterly revenue was down 5.6% on a year-over-year basis. Equities research analysts expect that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 23rd. Shareholders of record on Tuesday, October 1st were given a dividend of $0.236 per share. The ex-dividend date of this dividend was Tuesday, October 1st. This represents a $0.94 dividend on an annualized basis and a yield of 0.74%. Agilent Technologies’s payout ratio is 19.50%.

Insider Buying and Selling

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the completion of the sale, the senior vice president now directly owns 40,011 shares in the company, valued at $5,801,595. This represents a 19.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Padraig Mcdonnell sold 1,958 shares of the business’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the sale, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at approximately $3,497,110. This trade represents a 7.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,995 shares of company stock worth $1,739,510 in the last quarter.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.